NCT02833805View on ClinicalTrials.gov

NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

July 31, 2021

Study Completion Date

July 31, 2021

Conditions
Severe Aplastic AnemiaAplastic AnemiaBone Marrow FailureImmunosuppression
Interventions
DRUG

Thymoglobulin

Day -9: 0.5 mg/kg Days -8 and -7: 2 mg/kg daily

DRUG

Fludarabine

Days -6 through -2: 30 mg/m\^2 IV daily

DRUG

Cyclophosphamide

Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily

RADIATION

Total body irradiation

Day -1: 200 centigray (cGy) in a single fraction

DRUG

Tacrolimus

Start on Day 5 through Day 365

DRUG

Mycophenolate mofetil

Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)

Trial Locations (1)

21287

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT02833805 - NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia | Biotech Hunter | Biotech Hunter